What's Happening?
JLL is marketing a significant life sciences campus in Raritan Borough, Somerset County, New Jersey, for sale. The property, located at 1001 Route 202, spans 66.08 acres and includes 14 buildings totaling 596,183 square feet. This comprises 320,183 square feet of
lab and office space, 186,000 square feet for pharmaceutical manufacturing, and 63,000 square feet of warehouse space. The seller intends to close the sale in 2026 and will execute a sale-leaseback agreement through December 31, 2027. This arrangement is designed to provide immediate income for the investor while allowing ample time to secure site plan approvals and entitlements for future development. The site, formerly owned by Ortho-Clinical Diagnostics Inc., a Johnson & Johnson division, has undergone $9.4 million in capital improvements since 2021 and features a 1.7-megawatt owned solar array, robust power infrastructure, and on-site amenities.
Why It's Important?
This sale represents a significant opportunity within the U.S. life sciences real estate market, particularly in New Jersey, a hub for pharmaceutical and biotechnology industries. The short-term leaseback offers a unique investment structure, providing immediate revenue while mitigating vacancy risks for the buyer during a transitional period. The property's existing infrastructure, including lab and manufacturing space, a solar array, and strategic location with access to major interstates (I-287 and I-78), makes it highly attractive for continued life sciences operations or potential redevelopment. The OM-3 zoning allows for diverse uses such as lab and life science facilities, GMP manufacturing, and warehousing, catering to the evolving needs of the sector. The transaction could influence regional real estate trends, potentially attracting new businesses or expanding existing ones, thereby impacting local employment and economic growth in Somerset County.
What's Next?
The JLL team, including Jose Cruz, Dan Loughlin, Jeremy Neuer, Michael Kavaler, Nicholas Stefans, and Jason Lundy, will continue to market the property, with Ryan Carroll and Jason Benson advising on financing and leasing. The seller's plan to execute a sale-leaseback through December 31, 2027, indicates a structured transition period. During this time, the new owner will likely focus on pursuing site plan approvals and entitlements to maximize the property's potential under its OM-3 zoning. This could involve planning for repositioning or redevelopment into advanced lab facilities, manufacturing plants, or expanded warehousing. The outcome of this sale will be closely watched by other real estate investors and life sciences companies, as it could set precedents for future transactions in the region and signal confidence in the long-term growth of the U.S. life sciences sector.
Beyond the Headlines
The sale of this Somerset County life sciences campus underscores a broader trend in the U.S. commercial real estate market: the increasing demand for specialized properties that can support high-growth industries like biotechnology and pharmaceuticals. The inclusion of a 1.7-megawatt owned solar array highlights a growing emphasis on sustainable infrastructure and energy independence in commercial properties, reflecting both environmental consciousness and operational cost-saving strategies. The property's history, having been part of Johnson & Johnson and later acquired by Quidel Corp., illustrates the dynamic nature of corporate divestitures and acquisitions within the life sciences sector, which often leads to significant real estate opportunities. The strategic location in a region with a high average household income and a well-educated workforce further emphasizes the importance of human capital and regional ecosystems in attracting and retaining advanced industries.
